Biophan to Participate in Expert Panel on Intellectual Property at Pennsylvania Nanotechnology Conference.

ROCHESTER, N.Y. -- John Lanzafame, President of Biophan's Nanolution Drug-Delivery Division, to Discuss Patent-Building Strategies

Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology, has announced that John Lanzafame, President of the Nanolution drug delivery division of Biophan, is scheduled to participate on an expert panel at the Pennsylvania Nanotechnology Conference, to be held at the Westin Convention Center Hotel in Pittsburgh, PA, April 18-20.

Mr. Lanzafame is scheduled to take part in a panel entitled, "Emerging Nanotech Strategies: Getting the Biggest Bang for Your Buck," at 11 a.m., on April 20th. The panel is designed to present a range of perspectives from industry experts on strategies that can be employed to generate greater return on nanotech intellectual property investments. Mr. Lanzafame will discuss Biophan's strategies in the expansion of its intellectual property portfolio, including the Company's successful ongoing initiatives to create "patent thickets" to protect proprietary technologies and potential markets. Other topics expected to be covered include the importance of early planning in the patent process to ensure optimal value from intellectual property portfolios.

"Biophan is an intellectual property-driven company, and we have developed extensive experience in intellectual property development and strategies," said Mr. Lanzafame. "Since its inception, Biophan has pursued a very aggressive program to build up a commanding patent and intellectual property portfolio, at last count totaling 114 U.S. issued patents, licenses, or applications. It's an important part of our plan to deliver next-generation technology and cutting-edge products to the marketplace, while protecting these technologies and ensuring the greatest value for the Company and its shareholders."

About the Pennsylvania Nanotechnology Conference

The Pennsylvania Nanotechnology Conference represents the third major gathering on nanotechnology sponsored by the Commonwealth of Pennsylvania. Through formal presentations, displays, detailed documentation and informal meetings, participants will have the opportunity to learn about the technology, expand business opportunities, and make new contacts. Conference topics will include nanotechnology manufacturing and processing, electronics, semi-conductors, and instrumentation. Panel discussions will cover topics regarding emerging nanotech strategies, capitalization and international nanotechnology.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 36 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements 

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.